A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

Phase 3

Active, not recruiting

• Conditions: Carcinoma, Renal Cell
• Interventions: Drug: Cabozantinib; Drug: Belzutifan; Drug: Lenvatinib

• Registration Number: NCT04586231
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy.

The primary hypothesis is that belzutifan + lenvatinib is superior to cabozantinib in terms of progression-free survival or overall survival.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-10-09
• Study First Submitted QC: 2020-10-09
• Study First Posted: 2020-10-14
• Study Start: 2021-02-25
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-27
• Last Update Posted: 2025-04-02
• Primary Completion: 2026-02-11
• Study Completion: 2027-02-11

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 708

Inclusion Criteria

• Unresectable, locally advanced or metastatic clear cell renal cell carcinoma (RCC).
• Disease progression on or after an anti-programmed cell death-1/ligand 1 (PD-1/L1) therapy as either first or second-line treatment for locally advanced/metastatic RCC or as adjuvant treatment or neoadjuvant/adjuvant with progression on or within 6 months of last dose.
• Measurable disease per RECIST 1.1 criteria as assessed by local study investigator.
• Karnofsky performance status (KPS) score of at least 70% assessed within 10 days before randomization.
• Received no more than 2 prior systemic regimens including: one anti-PD-1/L1 containing adjuvant or neoadjuvant/adjuvant regimens with progression on or within 6 months from the last dose of that regimen OR one or 2 regimens for locoregional/advanced disease
• Received only 1 prior antiPD-1/L1 therapy for adjuvant, neoadjuvant/adjuvant or locally advanced/metastatic RCC.
• A male participant is eligible to participate if he is abstinent from heterosexual intercourse or agrees to use contraception during the intervention period and for at least 7 days after the last dose of belzutifan or lenvatinib in the belzutifan+lenvatinib arm, whichever occurs last, and 23 days after the last dose of cabozantinib.
• A female participant is eligible to participate if they are not pregnant, not breastfeeding, and at least 1 of the following conditions applies: Not a woman of childbearing potential (WOCBP) or a WOCBP who agrees to follow the contraceptive guidance during the intervention period and for at least 30 days after the last dose of study intervention in the belzutifan+ lenvatinib arm, or 120 days after the last dose of study intervention in the cabozantinib arm.
• Adequately controlled blood pressure.
• Adequate organ function.

Exclusion Criteria

• A pulse oximeter reading <92% at rest, requires intermittent supplemental oxygen, or requires chronic supplemental oxygen.
• Known additional malignancy that is progressing or has required active treatment within the past 3 years except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy.
• Known central nervous system (CNS) metastases and/or carcinomatous meningitis.
• Clinically significant cardiac disease within 6 months of first dose of study intervention.
• Prolongation of QTc interval to >480 ms.
• Symptomatic pleural effusion (e.g.,cough, dyspnea, pleuritic chest pain) that is not clinically stable.
• Pre-existing ≥Grade 3 gastrointestinal or nongastrointestinal fistula.
• Moderate to severe hepatic impairment.
• History of significant bleeding within 3 months before randomization.
• History of solid organ transplantation.
• Known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study.
• Unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption (e.g., gastrectomy, partial bowel obstruction, malabsorption).
• Known hypersensitivity or allergy to the active pharmaceutical ingredients or any component of the study intervention formulations.
• Received colony-stimulating factors [eg, granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GMCSF) or recombinant erythropoietin (EPO)] within 28 days before randomization.
• Prior treatment with belzutifan or another hypoxia-inducible factor (HIF)-2α inhibitor.
• Prior treatment with lenvatinib.
• Prior treatment with cabozantinib.
• Currently participating in a study of an investigational agent or using an investigational device.
• Active infection requiring systemic therapy.
• History of human immunodeficiency virus (HIV) infection.
• History of hepatitis B or known active hepatitis C infection.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Belzutifan + Lenvatinib	Lenvatinib	Belzutifan 120 mg and lenvatinib 20 mg orally once a day
Cabozantinib	Cabozantinib	Cabozantinib 60 mg orally once a day
Belzutifan + Lenvatinib	Belzutifan	Belzutifan 120 mg and lenvatinib 20 mg orally once a day

Primary Outcome Measures

Name	Time	Method
Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)	Up to approximately 34 months	PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review will be presented.
Overall Survival (OS)	Up to approximately 44 months	OS is defined as time from randomization to death due to any cause.

Secondary Outcome Measures

Name	Time	Method
Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)	Up to approximately 44 months	For participants who demonstrate a confirmed complete response (CR: Disappearance of all target lesions) or confirmed partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death. The DOR as assessed by blinded independent central review will be presented.
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)	Up to approximately 24 months	ORR is defined as the percentage of participants who have a complete response (CR: Disappearance of all target lesions) or a partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by blinded independent central review based on RECIST 1.1 will be presented.
Number of Participants Who Experienced One or More Adverse Events (AEs)	Up to approximately 44 months	An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)	Up to approximately 44 months	An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Trial Locations

Locations (184)

Confluence Health | Wenatchee Valley Hospital & Clinics ( Site 0061); 🇺🇸 Wenatchee, Washington, United States

Georgetown University Medical Center ( Site 0006); 🇺🇸 Washington, District of Columbia, United States

Memorial Sloan Kettering Cancer Center ( Site 0055); 🇺🇸 New York, New York, United States

University of Texas, Southwestern Medical Center ( Site 0015); 🇺🇸 Dallas, Texas, United States

Sanatorio Parque ( Site 0806); 🇦🇷 Rosario, Santa Fe, Argentina

Lyell McEwin Hospital ( Site 4004); 🇦🇺 Elizabeth Vale, South Australia, Australia

Klinik Ottakring-1.Medizinische Abteilung - Zentrum für Onkologie und Hämatologie ( Site 1031); 🇦🇹 Vienna, Wien, Austria

Grand Hopital de Charleroi ( Site 1104); 🇧🇪 Charleroi, Hainaut, Belgium

Cliniques Universitaires Saint Luc - Bruxelles ( Site 1105); 🇧🇪 Brussels, Bruxelles-Capitale, Region De, Belgium

UZ Leuven ( Site 1101); 🇧🇪 Leuven, Vlaams-Brabant, Belgium

Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0114); 🇨🇦 Hamilton, Ontario, Canada

BC Cancer Vancouver-Clinical Trials Unit ( Site 0110); 🇨🇦 Vancouver, British Columbia, Canada

CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0102); 🇨🇦 Sherbrooke, Quebec, Canada

Kingston Health Sciences Centre ( Site 0105); 🇨🇦 Kingston, Ontario, Canada

Tampereen yliopistollinen sairaala ( Site 1801); 🇫🇮 Tampere, Pirkanmaa, Finland

Clinique Francois Chenieux ( Site 1210); 🇫🇷 Limoges, Haute-Vienne, France

Tallaght University Hospital ( Site 3200); 🇮🇪 Dublin, Ireland

Hamamatsu University School of Medicine University Hospital ( Site 5004); 🇯🇵 Hamamatsu, Shizuoka, Japan

Amphia Hospital Location Molengracht ( Site 1912); 🇳🇱 Breda, Noord-Brabant, Netherlands

Samsung Medical Center ( Site 4201); 🇰🇷 Seoul, Korea, Republic of

Haga Ziekenhuis locatie Leyweg-Oncology ( Site 1917); 🇳🇱 Den Haag, Zuid-Holland, Netherlands

Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 2500); 🇷🇴 Cluj Napoca, Cluj, Romania

Hadassah Medical-Oncology department ( Site 2609); 🇷🇺 Moscow, Moskovskaya Oblast, Russian Federation

Volgograd Regional Uronephrological Center ( Site 2615); 🇷🇺 Volzhsky, Volgogradskaya Oblast, Russian Federation

Complejo Hospitalario Universitario A Coruna ( Site 1502); 🇪🇸 A Coruna, La Coruna, Spain

Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1507); 🇪🇸 Barcelona, Spain

Hospital Clinico San Carlos ( Site 1504); 🇪🇸 Madrid, Spain

Kantonsspital Graubuenden ( Site 1600); 🇨🇭 Chur, Grisons, Switzerland

Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 1604); 🇨🇭 Bellinzona, Ticino, Switzerland

Royal United Hospital Bath England ( Site 3108); 🇬🇧 Bath, Bath And North East Somerset, United Kingdom

Southend University Hospital ( Site 3112); 🇬🇧 Southend, Essex, United Kingdom

Liga Norte Riograndense Contra o Cancer ( Site 0313); 🇧🇷 Natal, Rio Grande Do Norte, Brazil

Cedars Sinai Medical Center ( Site 0027); 🇺🇸 Los Angeles, California, United States

UCLA Hematology/Oncology - Santa Monica ( Site 0048); 🇺🇸 Los Angeles, California, United States

UC Irvine Health ( Site 0029); 🇺🇸 Orange, California, United States

St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0095); 🇺🇸 Orange, California, United States

University Cancer & Blood Center, LLC ( Site 0057); 🇺🇸 Athens, Georgia, United States

Rush University Medical Center ( Site 0040); 🇺🇸 Chicago, Illinois, United States

Parkview Cancer Institute ( Site 0088); 🇺🇸 Fort Wayne, Indiana, United States

Lahey Hospital & Medical Center ( Site 0090); 🇺🇸 Burlington, Massachusetts, United States

HealthPartners Cancer Research Center-HealthPartners Frauenshuh Cancer Center ( Site 0005); 🇺🇸 Saint Louis Park, Minnesota, United States

Cancer & Hematology Centers of Western Michigan ( Site 0018); 🇺🇸 Grand Rapids, Michigan, United States

Cancer Partners of Nebraska ( Site 0086); 🇺🇸 Lincoln, Nebraska, United States

Rutgers Cancer Institute of New Jersey ( Site 0078); 🇺🇸 New Brunswick, New Jersey, United States

R.J. Zuckerberg Cancer Center-Medical Oncology ( Site 0013); 🇺🇸 Lake Success, New York, United States

Levine Cancer Institute ( Site 0004); 🇺🇸 Charlotte, North Carolina, United States

Duke Cancer Institute ( Site 0096); 🇺🇸 Durham, North Carolina, United States

Huntsman Cancer Institute-HCI Clinical Trials Office ( Site 7001); 🇺🇸 Salt Lake City, Utah, United States

Blue Ridge Cancer Care - Roanoke ( Site 0043); 🇺🇸 Roanoke, Virginia, United States

Seattle Cancer Care Alliance-Renal/Melanoma/MCC ( Site 0093); 🇺🇸 Seattle, Washington, United States

Hospital Británico de Buenos Aires-Oncology ( Site 0801); 🇦🇷 Ciudad autónoma de Buenos Aires, Buenos Aires, Argentina

Centro de Urología (CDU) ( Site 0803); 🇦🇷 Caba, Buenos Aires, Argentina

Instituto Alexander Fleming ( Site 0800); 🇦🇷 Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

Sanatorio Británico-Clinical Oncology Department ( Site 0802); 🇦🇷 Rosario, Santa Fe, Argentina

GenesisCare North Shore ( Site 4011); 🇦🇺 St Leonards, New South Wales, Australia

Asociación de Beneficencia Hospital Sirio Libanés ( Site 0804); 🇦🇷 Buenos Aires, Argentina

Ordensklinikum Linz GmbH Elisabethinen-Urologie ( Site 1001); 🇦🇹 Linz, Oberosterreich, Austria

Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 4010); 🇦🇺 Melbourne, Victoria, Australia

Medizinische Universitätsklinik Graz ( Site 1051); 🇦🇹 Graz, Steiermark, Austria

Medizinische Universität Wien ( Site 1021); 🇦🇹 Wien, Austria

CHU de Liege ( Site 1102); 🇧🇪 Liege, Belgium

UZ Gent ( Site 1100); 🇧🇪 Gent, Oost-Vlaanderen, Belgium

Hospital Paulistano - Amil Clinical Research ( Site 0308); 🇧🇷 Sao Paulo, Brazil

BP - A Beneficencia Portuguesa de São Paulo-Medical Oncology ( Site 0311); 🇧🇷 Sao Paulo, Brazil

Tom Baker Cancer Centre ( Site 0109); 🇨🇦 Calgary, Alberta, Canada

The Ottawa Hospital - General Campus-The Ottawa Hospital Cancer Centre ( Site 0116); 🇨🇦 Ottawa, Ontario, Canada

Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0; 🇨🇦 Quebec, Canada

CISSS de la Monteregie-Centre ( Site 0103); 🇨🇦 Greenfield Park, Quebec, Canada

Sunnybrook Health Sciences - Odette Cancer Centre ( Site 0113); 🇨🇦 Toronto, Ontario, Canada

James Lind Centro de Investigación del Cáncer ( Site 0402); 🇨🇱 Temuco, Araucania, Chile

Instituto Nacional de Cancerología-Clinical Oncology ( Site 0500); 🇨🇴 Bogotá, Cundinamarca, Colombia

Fundación Cardiovascular de Colombia ( Site 0501); 🇨🇴 Piedecuesta, Santander, Colombia

Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 2203); 🇨🇿 Brno, Brno-mesto, Czechia

Fakultni Thomayerova nemocnice-Onkologicka klinika 1. LF UK ( Site 2200); 🇨🇿 Prague, Praha 4, Czechia

Nemocnice České Budějovice-Onkologicke oddeleni ( Site 2204); 🇨🇿 České Budějovice, Jihocesky Kraj, Czechia

Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 2205); 🇨🇿 Praha, Praha 5, Czechia

Fakultni nemocnice Hradec Kralove-Klinika onkologie a radioterapie ( Site 2201); 🇨🇿 Hradec Kralove, Czechia

HYKS ( Site 1800); 🇫🇮 Helsinki, Uusimaa, Finland

TYKS ( Site 1802); 🇫🇮 Turku, Varsinais-Suomi, Finland

Institut Jean Godinot ( Site 1216); 🇫🇷 Reims, Ain, France

Institut Claudius Regaud ( Site 1215); 🇫🇷 Toulouse, Haute-Garonne, France

Hopital Tenon ( Site 1213); 🇫🇷 Paris, France

Institut de Cancerologie de l Ouest Site Paul Papin ( Site 1200); 🇫🇷 Angers, Maine-et-Loire, France

Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 1201); 🇫🇷 Saint Herblain, Loire-Atlantique, France

NCT-Department of Medical Oncology ( Site 1320); 🇩🇪 Heidelberg, Baden-Wurttemberg, Germany

Klinik fuer Urologie ( Site 1303); 🇩🇪 Freiburg, Baden-Wurttemberg, Germany

Universitaetsklinikum Frankfurt ( Site 1301); 🇩🇪 Frankfurt am Main, Hessen, Germany

Klinikum Nuernberg Nord ( Site 1300); 🇩🇪 Nuremberg, Bayern, Germany

Helios Klinikum Erfurt GmbH ( Site 1315); 🇩🇪 Erfurt, Thuringen, Germany

Universitaetsklinikum Aachen AOER ( Site 1317); 🇩🇪 Aachen, Nordrhein-Westfalen, Germany

Krankenhaus Martha Maria Halle-Doelau ( Site 1314); 🇩🇪 Halle, Sachsen-Anhalt, Germany

Universitaetsklinikum des Saarlandes ( Site 1305); 🇩🇪 Homburg/ Saar, Saarland, Germany

HELIOS Klinikum Berlin-Buch ( Site 1311); 🇩🇪 Berlin, Germany

Charite Universitaetsmedizin Berlin ( Site 1321); 🇩🇪 Berlin, Germany

UNIVERSITY HOSPITAL OF PATRAS-DIVISION OF ONCOLOGY ( Site 3302); 🇬🇷 Patras, Achaia, Greece

Athens Medical Center ( Site 3303); 🇬🇷 Athens, Attiki, Greece

European Interbalkan Medical Center-Oncology Department ( Site 3300); 🇬🇷 Thessaloniki, Greece

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 1407); 🇮🇹 Meldola, Forli-Cesena, Italy

Mater Private Hospital - Dublin ( Site 3202); 🇮🇪 Dublin, Ireland

Mater Misericordiae University Hospital ( Site 3201); 🇮🇪 Dublin 7, Dublin, Ireland

Istituto Clinico Humanitas Research Hospital ( Site 1406); 🇮🇹 Rozzano, Milano, Italy

Ospedale San Luigi Gonzaga ( Site 1405); 🇮🇹 Orbassano, Torino, Italy

Medical Oncology Ospedale San Donato ( Site 1404); 🇮🇹 Arezzo, Italy

Azienda Ospedaliera Policlinico di Bari ( Site 1402); 🇮🇹 Bari, Italy

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 1400); 🇮🇹 Milano, Italy

IRCCS Ospedale San Raffaele ( Site 1409); 🇮🇹 Milano, Italy

Istituti Clinici Scientifici Maugeri Spa ( Site 1403); 🇮🇹 Pavia, Italy

Fondazione Policlinico Universitario Agostino Gemelli-Medical Oncology ( Site 1410); 🇮🇹 Roma, Italy

Azienda Ospedaliera S. Maria di Terni ( Site 1401); 🇮🇹 Terni, Italy

National Cancer Center Hospital East ( Site 5000); 🇯🇵 Kashiwa, Chiba, Japan

Toho University Sakura Medical Center ( Site 5014); 🇯🇵 Sakura, Chiba, Japan

Ospedale Maggiore Borgo Trento ( Site 1408); 🇮🇹 Verona, Italy

Fujita Health University ( Site 5003); 🇯🇵 Toyoake, Aichi, Japan

Kobe City Medical Center General Hospital ( Site 5017); 🇯🇵 Kobe, Hyogo, Japan

Sapporo Medical University Hospital ( Site 5008); 🇯🇵 Sapporo, Hokkaido, Japan

Nara Medical University Hospital ( Site 5002); 🇯🇵 Kashihara, Nara, Japan

Yokohama City University Hospital ( Site 5007); 🇯🇵 Yokohama, Kanagawa, Japan

Kindai University Hospital- Osakasayama Campus-Urology ( Site 5010); 🇯🇵 Osakasayama, Osaka, Japan

Toranomon Hospital ( Site 5001); 🇯🇵 Minato-ku, Tokyo, Japan

Osaka University Hospital ( Site 5012); 🇯🇵 Suita, Osaka, Japan

Tokyo Medical and Dental University Hospital ( Site 5009); 🇯🇵 Bunkyo-ku, Tokyo, Japan

Kyushu University Hospital ( Site 5005); 🇯🇵 Fukuoka, Japan

Nippon Medical School Hospital ( Site 5006); 🇯🇵 Tokyo, Japan

Tokyo Women's Medical University Adachi Medical Center ( Site 5015); 🇯🇵 Tokyo, Japan

Asan Medical Center ( Site 4200); 🇰🇷 Seoul, Korea, Republic of

Chonnam National University Hwasun Hospital-Oncology ( Site 4203); 🇰🇷 Hwasun, Jeonranamdo, Korea, Republic of

Zuyderland Medical Centre-Trialbureau Interne Geneeskunde ( Site 1904); 🇳🇱 Sittard-Geleen, Limburg, Netherlands

Erasmus MC ( Site 1913); 🇳🇱 Rotterdam, Zuid-Holland, Netherlands

Franciscus Gasthuis & Vlietland, Locatie Vlietland ( Site 1909); 🇳🇱 Schiedam, Zuid-Holland, Netherlands

Universitair Medisch Centrum Utrecht ( Site 1910); 🇳🇱 Utrecht, Netherlands

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 2400); 🇵🇱 Warszawa, Mazowieckie, Poland

Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 2402); 🇵🇱 Bydgoszcz, Kujawsko-pomorskie, Poland

Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 2401); 🇵🇱 Poznan, Wielkopolskie, Poland

Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 2501); 🇷🇴 Cluj Napoca, Cluj, Romania

Centrul de Oncologie "Sfântul Nectarie" ( Site 2502); 🇷🇴 Craiova, Dolj, Romania

Ivanovo Regional Oncology Dispensary ( Site 2616); 🇷🇺 Ivanovo, Ivanovskaya Oblast, Russian Federation

MEDSI Clinical Hospital on Pyatnitsky Highway-Departmentof Antitumor Drug therapy ( Site 2618); 🇷🇺 Krasnogorsk, Moskovskaya Oblast, Russian Federation

SHI of Moscow City Oncology Clinical Hospital - 62 ( Site 2614); 🇷🇺 Moscow, Moskva, Russian Federation

FSBI United Hospital with Polyclinic ( Site 2613); 🇷🇺 Moscow, Moskva, Russian Federation

Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1508); 🇪🇸 Madrid, Madrid, Comunidad De, Spain

Hospital Clinic i Provincial ( Site 1500); 🇪🇸 Barcelona, Spain

Hospital Santa Creu i Sant Pau ( Site 1501); 🇪🇸 Barcelona, Spain

Hospital General Universitario Gregorio Maranon ( Site 1505); 🇪🇸 Madrid, Spain

Hospital Virgen del Rocio ( Site 1503); 🇪🇸 Sevilla, Spain

Universitaetsspital Zuerich ( Site 1601); 🇨🇭 Zuerich, Zurich, Switzerland

Nottingham University Hospitals NHS Trust. City Hospital Campus ( Site 3106); 🇬🇧 Nottingham, England, United Kingdom

Aberdeen Royal Infirmary-Department of Oncology ( Site 3105); 🇬🇧 Aberdeen, Aberdeen City, United Kingdom

Imperial Healthcare NHS Trust Charing Cross Hospital ( Site 3107); 🇬🇧 London, London, City Of, United Kingdom

Mount Vernon Cancer Centre ( Site 3101); 🇬🇧 Northwood, London, City Of, United Kingdom

Providence Saint John's Health Center ( Site 0083); 🇺🇸 Santa Monica, California, United States

Emory University Hospital ( Site 0012); 🇺🇸 Atlanta, Georgia, United States

Illinois Cancer Care, PC ( Site 0008); 🇺🇸 Peoria, Illinois, United States

Lehigh Valley Hospital- Cedar Crest-Oncology Clinical Trials ( Site 0056); 🇺🇸 Allentown, Pennsylvania, United States

CHU de Bordeaux- Hopital Saint Andre ( Site 1209); 🇫🇷 Bordeaux, Gironde, France

University of Vermont Medical Center ( Site 0001); 🇺🇸 Burlington, Vermont, United States

Ironwood Cancer & Research Centers ( Site 0077); 🇺🇸 Chandler, Arizona, United States

Krankenhaus der Barmherzigen Brüder Wien ( Site 1041); 🇦🇹 Wien, Austria

Fundación Colombiana de Cancerología Clínica Vida ( Site 0505); 🇨🇴 Medellin, Antioquia, Colombia

Bradfordhill-Clinical Area ( Site 0400); 🇨🇱 Santiago, Region M. De Santiago, Chile

Cross Cancer Institute ( Site 0111); 🇨🇦 Edmonton, Alberta, Canada

Peninsula Health Frankston Hospital ( Site 4001); 🇦🇺 Frankston, Victoria, Australia

Centre Antoine Lacassagne ( Site 1217); 🇫🇷 Nice, Alpes-Maritimes, France

Antoni van Leeuwenhoek Ziekenhuis ( Site 1901); 🇳🇱 Amsterdam, Noord-Holland, Netherlands

The Moncton Hospital ( Site 0101); 🇨🇦 Moncton, New Brunswick, Canada

Alexandra General Hospital of Athens-ONCOLOGY DEPT. ( Site 3304); 🇬🇷 Athens, Attiki, Greece

Niigata University Medical & Dental Hospital ( Site 5013); 🇯🇵 Niigata, Japan

Yaroslavl Regional Cancer Hospital-Oncology ( Site 2619); 🇷🇺 Yaroslavl, Yaroslavskaya Oblast, Russian Federation

Musgrove Park Hospital ( Site 3103); 🇬🇧 Taunton, Somerset, United Kingdom

Sociedad De Oncologia Y Hematologia Del Cesar-Oncology ( Site 0508); 🇨🇴 Valledupar, Cesar, Colombia

Singleton Hospital ( Site 3111); 🇬🇧 Swansea, Wales, United Kingdom

Institut Jules Bordet ( Site 1103); 🇧🇪 Anderlecht, Bruxelles-Capitale, Region De, Belgium

ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 3301); 🇬🇷 Chaidari, Attiki, Greece

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - O-Klinika Onkologii Klinicznej ( Site 240; 🇵🇱 Krakow, Malopolskie, Poland

University of Mississippi Medical Ctr ( Site 0037); 🇺🇸 Jackson, Mississippi, United States

Institut de cancérologie Strasbourg Europe (ICANS) ( Site 1218); 🇫🇷 Strasbourg, Alsace, France

Osaka International Cancer Institute ( Site 5016); 🇯🇵 Osaka, Japan

Medisch Centrum Leeuwarden ( Site 1905); 🇳🇱 Leeuwarden, Fryslan, Netherlands

Keio university hospital ( Site 5011); 🇯🇵 Tokyo, Japan

Hopitaux Universitaires de Geneve HUG ( Site 1602); 🇨🇭 Geneva, Geneve, Switzerland

AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlando ( Site 0003); 🇺🇸 Orlando, Florida, United States

Orlando Health, Inc. ( Site 0035); 🇺🇸 Orlando, Florida, United States

Norton Cancer Institute - St. Matthews ( Site 0065); 🇺🇸 Louisville, Kentucky, United States

Tulane University School of Medicine ( Site 0098); 🇺🇸 New Orleans, Louisiana, United States

Centro Gaucho Integrado de Oncologia ( Site 0304); 🇧🇷 Porto Alegre, Rio Grande Do Sul, Brazil